Additional file 2 of Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy

Additional file 2: Table S1a. Power at 5% significance level by odds ratio for 3351 controls and specified number of cases, for ABI3 with MAF of 0.8 % in controls. Table S1b Power at 5% significance level by odds ratio for 3351 controls and specified number of cases, for PLCG2 with MAF of 1.09 % in controls. Table S2. (A) Braak stage and (B) Thal phase distribution in the PSP and LBD cohorts based on (1) ABI3_rs616338_C_T and (2) PLCG2_rs72824905_C_G genotypes. The total number of subjects and percentage (N (%)) are shown for those subjects with Braak and Thal measures. For each series, the number of carriers with the minor allele, the major allele, and all subjects with a genotype for the given SNP are shown, respectively. The percentage is the N for each neuropathologic category for a given genotype divided by the total N of each series. Braak stage and Thal phase categories are defined as per prior published criteria. Abbreviations: PSP progressive supranuclear palsy, LBD dementia with Lewy bodies. Genotypes for ABI3(rs616338)-(TT/CT/CC) and PLCG2(rs72824905)-(GG/CG/CC). Given their rarity, there were no individuals with ABI3(rs616338)_TT or PLCG2(rs72824905)_GG genotypes.